vTv Therapeutics Inc. (NASDAQ:VTVT - Get Free Report) saw a significant decline in short interest during the month of May. As of May 15th, there was short interest totalling 16,400 shares, a decline of 24.1% from the April 30th total of 21,600 shares. Currently, 1.1% of the shares of the stock are short sold. Based on an average daily volume of 21,600 shares, the short-interest ratio is currently 0.8 days.
Institutional Trading of vTv Therapeutics
A number of large investors have recently made changes to their positions in VTVT. Connective Capital Management LLC purchased a new stake in shares of vTv Therapeutics during the first quarter valued at $162,000. JPMorgan Chase & Co. purchased a new stake in shares of vTv Therapeutics during the fourth quarter valued at $25,000. Finally, Geode Capital Management LLC boosted its stake in shares of vTv Therapeutics by 12.9% during the fourth quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company's stock valued at $158,000 after purchasing an additional 1,327 shares during the period. 17.51% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several equities research analysts recently weighed in on VTVT shares. Wall Street Zen started coverage on shares of vTv Therapeutics in a research report on Wednesday, April 16th. They issued a "sell" rating on the stock. HC Wainwright started coverage on shares of vTv Therapeutics in a research report on Wednesday, April 9th. They issued a "buy" rating and a $36.00 price target on the stock.
Get Our Latest Report on vTv Therapeutics
vTv Therapeutics Stock Performance
NASDAQ VTVT traded up $0.53 on Thursday, hitting $16.53. 735 shares of the stock were exchanged, compared to its average volume of 23,360. The stock has a fifty day moving average price of $19.14 and a two-hundred day moving average price of $17.22. The firm has a market capitalization of $52.80 million, a P/E ratio of -3.65 and a beta of 0.77. vTv Therapeutics has a 52-week low of $12.12 and a 52-week high of $26.99.
vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last posted its quarterly earnings data on Thursday, May 15th. The biotechnology company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.04).
About vTv Therapeutics
(
Get Free Report)
vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.
Recommended Stories
Before you consider vTv Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and vTv Therapeutics wasn't on the list.
While vTv Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
